Recent studies suggested that immune checkpoints such as programmed cell death 1-ligand 1 (PD-L1), CD276, and CD47 are upregulated in CSCs, which helps them evade immune surveillance in tumor initiation, progression, and metastasis [[11], [12], [13], [14]]. The gene discussed is CD274; the disease is neoplasm.